April 16 (Reuters) - Bristol-Myers Squibb Co:
* BRISTOL-MYERS SQUIBB ANNOUNCES WORLDWIDE COLLABORATION WITH JANSSEN TO DEVELOP & COMMERCIALIZE BRISTOL-MYERS' FACTOR XIA INHIBITOR, BMS-986177
* BRISTOL-MYERS SQUIBB SAYS JANSSEN WILL PAY CO UPFRONT SUM ALONG WITH POTENTIAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS
* BRISTOL-MYERS SQUIBB SAYS CO, JANSSEN EXPECTED TO ADVANCE BMS-986177 INTO PHASE 2 CLINICAL TRIALS IN H2 2018 FOR STUDY OF SECONDARY STROKE PREVENTION Source text for Eikon: Further company coverage:
